查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1699059

門診腫瘤輸液市場成長、規模和趨勢分析（按產品、應用、療法和模式）—區域展望、競爭策略和細分預測（至 2034 年）

Outpatient Oncology Infusion Market Growth, Size, Trends Analysis - By Product, By Application, By Therapy, By Mode - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 260 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到 2034 年全球門診腫瘤輸液市場規模將達到 74.6 億美元，複合年成長率為 10.86%。

門診腫瘤輸注是指在門診進行無需住院的癌症治療，如免疫治療、化療、標靶治療等。患者在診所、門診護理中心或專門輸液中心的醫療監督下接受輸液治療。該策略在確保安全有效的治療的同時，提高了患者的便利性，降低了醫療成本，並縮短了住院時間。

治療費用高、報銷程序複雜以及患者的經濟限制是市場面臨的一些挑戰。腫瘤科護理師和藥劑師的短缺使得服務提供變得更具挑戰性。此外，還需要嚴格的程序和監控來限制藥物不良反應並確保門診病人的安全。

本報告調查了全球門診腫瘤輸液市場，並提供了市場的全面概述、市場影響因素和市場機會的分析、市場規模的趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局以及主要企業的概況。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場動態

  • 促進因素、阻礙因素、機會與挑戰分析

第5章 市場變數與展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 熱圖分析

第6章 競爭格局

  • 製造地、銷售區域、產品類型分佈
  • 併購、合作、產品發布與合作

7. 全球門診腫瘤輸液市場（依產品）

  • 點滴幫浦
  • 靜脈注射套件
  • 靜脈插管
  • 無針頭連接器

8. 全球門診腫瘤輸液市場（依應用）

  • 肺癌
  • 肝癌
  • 乳癌
  • 攝護腺癌

9. 全球門診腫瘤輸液市場（依治療方法）

  • 化療
  • 標靶治療
  • 免疫療法
  • 荷爾蒙療法

第10章全球門診腫瘤輸液市場（按模式）

  • 肌肉注射（IM）
  • 靜脈注射（IV）
  • 皮下

第 11 章全球門診腫瘤輸液市場

  • 全球門診腫瘤輸液市場規模及市場佔有率

第 12 章全球門診腫瘤輸液市場（按地區）

  • 亞太地區
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 埃及
    • 摩洛哥
    • 奈及利亞
    • 其他
  • 北美洲
    • 加拿大
    • 墨西哥
    • 美國
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他

第13章 公司簡介

  • B. Braun Melsungen AG
  • Baxter
  • Becton, Dickinson, and Company
  • Fresenius Kabi
  • ICU Medical, Inc
  • IRadimed Corporation
  • Medtronic PLC
  • Micrel Medical Devices SA
  • Moog, Inc.
  • Nipro Corporation
  • 其他

第14章結論

第 15 章簡稱表

第16章參考連結

簡介目錄
Product Code: HLCA2582

Outpatient Oncology Infusion Market Introduction and Overview

According to SPER market research, 'Global Outpatient Oncology Infusion Market Size- By Product, By Application, By Therapy, By Mode - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Outpatient Oncology Infusion Market is predicted to reach 7.46 billion by 2034 with a CAGR of 10.86%.

Outpatient oncology infusion represents the delivery of cancer treatments, such as immunotherapy, chemotherapy, or targeted therapy, in an outpatient setting without the need for hospital. Patients get intravenous drugs under medical supervision at clinics, ambulatory care centres, or specialist infusion centres. While ensuring safe and efficient treatment, this strategy improves patient convenience, lowers medical costs, and shortens hospital stays.

Restraints: High treatment costs, complicated reimbursement procedures, and patient financial constraints are some of the issues facing the outpatient oncology infusion business. Service delivery is further strained by a lack of qualified oncology nurses and pharmacists. Strict procedures and oversight are also necessary for controlling adverse medication responses and guaranteeing patient safety in outpatient settings.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Product, By Application, By Therapy, By Mode.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

      • B. Braun Melsungen AG, Baxter, Becton, Dickinson, and Company, Fresenius Kabi, ICU Medical, Inc, IRadimed Corporation, Medtronic PLC, Micrel Medical Devices SA, Moog, Inc., Nipro Corporation. and others.

Outpatient Oncology Infusion Market Segmentation:

By Product: Based on the Product, Global Outpatient Oncology Infusion Market is segmented as; Infusion pumps, Intravenous sets, IV cannulas, Needleless connectors.

By Application: Based on the Application, Global Outpatient Oncology Infusion Market is segmented as; Lung cancer, Liver cancer, Breast cancer, Prostate cancer.

By Therapy: Based on the Therapy, Global Outpatient Oncology Infusion Market is segmented as; Chemotherapy, Targeted therapy, Immunotherapy, Hormonal therapy.

By Mode: Based on the Mode, Global Outpatient Oncology Infusion Market is segmented as; Intramuscular (IM), Intravenous (IV), Subcutaneous.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPERs internal database
    • 2.1.4. Premium insight from KOLs
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTERs Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Outpatient Oncology Infusion Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Outpatient Oncology Infusion Market

7. Global Outpatient Oncology Infusion Market, By Product (USD Million) 2021-2034

  • 7.1. Infusion pumps
  • 7.2. Intravenous sets
  • 7.3. IV cannulas
  • 7.4. Needleless connectors

8. Global Outpatient Oncology Infusion Market, By Application (USD Million) 2021-2034

  • 8.1. Lung cancer
  • 8.2. Liver cancer
  • 8.3. Breast cancer
  • 8.4. Prostate cancer

9. Global Outpatient Oncology Infusion Market, By Therapy (USD Million) 2021-2034

  • 9.1. Chemotherapy
  • 9.2. Targeted therapy
  • 9.3. Immunotherapy
  • 9.4. Hormonal therapy

10. Global Outpatient Oncology Infusion Market, By Mode (USD Million) 2021-2034

  • 10.1. Intramuscular (IM)
  • 10.2. Intravenous (IV)
  • 10.3. Subcutaneous

11. Global Outpatient Oncology Infusion Market, (USD Million) 2021-2034

  • 11.1. Global Outpatient Oncology Infusion Market Size and Market Share

12. Global Outpatient Oncology Infusion Market, By Region, (USD Million) 2021-2034

  • 12.1. Asia-Pacific
    • 12.1.1. Australia
    • 12.1.2. China
    • 12.1.3. India
    • 12.1.4. Japan
    • 12.1.5. South Korea
    • 12.1.6. Rest of Asia-Pacific
  • 12.2. Europe
    • 12.2.1. France
    • 12.2.2. Germany
    • 12.2.3. Italy
    • 12.2.4. Spain
    • 12.2.5. United Kingdom
    • 12.2.6. Rest of Europe
  • 12.3. Middle East and Africa
    • 12.3.1. Kingdom of Saudi Arabia
    • 12.3.2. United Arab Emirates
    • 12.3.3. Qatar
    • 12.3.4. South Africa
    • 12.3.5. Egypt
    • 12.3.6. Morocco
    • 12.3.7. Nigeria
    • 12.3.8. Rest of Middle-East and Africa
  • 12.4. North America
    • 12.4.1. Canada
    • 12.4.2. Mexico
    • 12.4.3. United States
  • 12.5. Latin America
    • 12.5.1. Argentina
    • 12.5.2. Brazil
    • 12.5.3. Rest of Latin America

13. Company Profile

  • 13.1. B. Braun Melsungen AG
    • 13.1.1. Company details
    • 13.1.2. Financial outlook
    • 13.1.3. Product summary
    • 13.1.4. Recent developments
  • 13.2. Baxter
    • 13.2.1. Company details
    • 13.2.2. Financial outlook
    • 13.2.3. Product summary
    • 13.2.4. Recent developments
  • 13.3. Becton, Dickinson, and Company
    • 13.3.1. Company details
    • 13.3.2. Financial outlook
    • 13.3.3. Product summary
    • 13.3.4. Recent developments
  • 13.4. Fresenius Kabi
    • 13.4.1. Company details
    • 13.4.2. Financial outlook
    • 13.4.3. Product summary
    • 13.4.4. Recent developments
  • 13.5. ICU Medical, Inc
    • 13.5.1. Company details
    • 13.5.2. Financial outlook
    • 13.5.3. Product summary
    • 13.5.4. Recent developments
  • 13.6. IRadimed Corporation
    • 13.6.1. Company details
    • 13.6.2. Financial outlook
    • 13.6.3. Product summary
    • 13.6.4. Recent developments
  • 13.7. Medtronic PLC
    • 13.7.1. Company details
    • 13.7.2. Financial outlook
    • 13.7.3. Product summary
    • 13.7.4. Recent developments
  • 13.8. Micrel Medical Devices SA
    • 13.8.1. Company details
    • 13.8.2. Financial outlook
    • 13.8.3. Product summary
    • 13.8.4. Recent developments
  • 13.9. Moog, Inc.
    • 13.9.1. Company details
    • 13.9.2. Financial outlook
    • 13.9.3. Product summary
    • 13.9.4. Recent developments
  • 13.10. Nipro Corporation
    • 13.10.1. Company details
    • 13.10.2. Financial outlook
    • 13.10.3. Product summary
    • 13.10.4. Recent developments
  • 13.11. Others

14. Conclusion

15. List of Abbreviations

16. Reference Links